Immunomodulatory Effect and Biological Significance of β-Glucans

Structure and nanotoxicity of fungal chitin-glucan nanofibrils with gradient acid and alkaline treatments

Among nanoscale biopolymers, fungal chitin nanofibrils (ChNFs) stand out for their low carbon footprint and functional properties. However, the nanotoxicity properties of ChNFs have not been fully elucidated. To fill this knowledge gap, here we investigate the cytotoxicity and inflammatory effects of chemically modified ChNFs having gradient acid and alkaline treatments. ChNFs isolated from white mushroom exhibit a long fibrous morphology with diameters of 3-8 nm and lengths of 150-600 nm, and are composed of α-chitin in coexistence with amorphous covalently bounded β-glucans. Both alkaline (2 m NaOH) and acidic (2 m HCl) treatments impact the crystallinity, N-acetylation, zeta potential, and nitrogen content values to provide ranges of 23-to-51 %, 45-to-99 %, -5 to +26 mV, and 2.6-to-5.2 %, respectively. Nanotoxicity studies with colloidal dispersions demonstrate differences in the inflammatory response by cells after chemical post-treatments. The NaOH-treated ChNFs elicited a much lower inflammatory response, attenuating the release of nitrites and the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). Alginate hydrogels with ChNFs were further fabricated and demonstrated potential to host cells in three-dimensional microenvironments, preserving a good metabolic activity, viability, and cell proliferation. These results may guide new applications of fungal nanochitin in pharmaceutical or tissue engineering.

Type I interferon signaling controls the early hematopoietic expansion in response to β-glucan

Rapid hematopoietic adaptations are important for building and sustaining the biological response to β-glucan. The signals involved in these early events have not yet been fully explored. Given that type I interferons are produced in response to β-glucan and can profoundly impact hematopoietic stem cell (HSC) function, we hypothesized that this pathway may be involved in the early bone marrow response to β-glucan. In vivo administration of β-glucan led to local interferon-α production in the peritoneal cavity and bone marrow, upregulation of its receptor, IFNAR1, specifically on long-term hematopoietic stem cells (LT-HSCs), and broad expansion of downstream progenitor subpopulations. We demonstrate that intact type I interferon signaling is critical for β-glucan-mediated LT-HSC proliferation, mitochondrial activity, and glycolytic commitment. By determining that type I interferon signaling is important for LT-HSCs, which sit at the apex of the hematopoietic hierarchy, we uncover an important component of the early inflammatory response to β-glucan.

Breaking the virus: Yeast glucans as an effective alternative to acyclovir in HSVI treatment

Glucans, structural polysaccharides in the yeast cell wall, are known for their biological and immunomodulatory capacities, helping in prevention and management of infections. Herpes simplex virus type 1 (HSVI) is a prevalent infection that causes great comorbidity and is challenging to treat due to the adverse effects of standard antiviral drugs like acyclovir. This study assessed the potential of yeast glucans extracted from two different origins - a steviol-glycoside producing strain and a wild-type strain- to circumvent HSVI infection, either in vitro and ex vivo. Treatment with glucans in keratinocytes and macrophages in vitro reduced cell infection similarly to acyclovir. However, unlike acyclovir, glucans demonstrated an immunostimulatory effect, increasing the production of IL-1β, TNF-α and IL-6. Additionally, both glucans were formulated with squalane for skin application. This formulation improved glucans penetration in the skin, restored skin structure and reduced the cytopathic effect of HSVI infection. In summary, this study highlights yeast glucans as a natural therapeutic alternative for HSVI treatment, offering an option with an excellent safety profile. Moreover, using glucans from industrial side-streams promotes a sustainable approach, contributing to the circular economy.

Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside

The development of nucleic acid and protein drugs for oral delivery has lagged behind their production for conventional nonoral routes. Over the past decade, the evolution of DNA- and RNA-based technologies combined with the innovation of state-of-the-art delivery vehicles for nucleic acids has brought rapid advancements to the biopharmaceutical field. Nucleic acid therapies have the potential to achieve long-lasting effects, or even cures, by inhibiting or editing genes, which is not possible with conventional small-molecule drugs. However, challenges and limitations must be addressed before these therapies can provide cures for chronic conditions and rare diseases, rather than only offering temporary relief. Nucleic acids and proteins face premature degradation in the acidic, enzyme-rich stomach environment and are rapidly cleared by the liver. To overcome these challenges, various delivery vehicles have been developed to transport therapeutic compounds to the intestines, where the active compounds are released and gut microbiota and mucosal immune system also play an important role. This review provides a comprehensive overview of the promises and pitfalls associated with the oral route of administration of biologics, current delivery systems, applications of orally delivered therapeutics, and the challenges and considerations for translation of nucleic acid and protein therapeutics into clinical practice.

Exploring the Properties and Application Potential of β-Glucan in Skin Care

β-glucan is a natural polysaccharide widely found in plants, fungi, bacteria, and algae. Due to its significant immunomodulatory effects, it has become an important source for functional foods and pharmaceuticals. In addition to immune regulation, β-glucan also exhibits various bioactivities, including antioxidant, anti-inflammatory, barrier repair, and moisturizing effects, demonstrating great potential for applications in skin care. Its biological activity is influenced by factors such as its source, molecular structure, and physicochemical properties. This review systematically explores the relationship between the properties and functions of β- glucan, investigates its biological mechanisms, and summarizes its clinical applications and future prospects in skin care. The aim of this paper is to provide theoretical support for the development of β-glucan in the field of skin health and offer references for future related research and clinical practice.

Beta-Glucans in Biotechnology: A Holistic Review with a Special Focus on Yeast

Beta-glucans (β-glucans) are polysaccharides with significant biological activity, widely recognized for their immunomodulatory, anti-inflammatory, and metabolic health benefits. Among various sources, yeast-derived β-(1 → 3), (1 → 6)-glucans have gained particular attention due to their potent bioactivity and diverse applications in biotechnology, pharmaceuticals, and functional foods. This review comprehensively examines yeast β-glucans, covering their biosynthesis, extraction, and purification from industrially relevant yeast strains, particularly Saccharomyces cerevisiae. The impact of fermentation parameters on β-glucan yield and structural properties is analyzed, highlighting advancements in optimizing microbial production. Furthermore, we discuss methods for characterizing yeast β-glucans, including analytical and bioassay techniques, and compare their physicochemical properties with those of β-glucans from other sources. Finally, this review explores the therapeutic potential of yeast-derived β-glucans, focusing on their role in immunomodulation and metabolic regulation and their emerging applications in biomedicine, functional foods, and industrial formulations. By synthesizing recent advancements, this work provides insights into the expanding utilization of yeast β-glucans and their potential for future biotechnological developments.

Comparative Research of Antioxidant, Antimicrobial, Antiprotozoal and Cytotoxic Activities of Edible Suillus sp. Fruiting Body Extracts

The aim of this study was to evaluate bioactive properties of Basidiomycota fungi, mainly Suillus sp. Wide spectrum of activities were revealed for S. variegatus, S. luteus, S. bovinus and S. granulatus; and obtained results were compared with other common fungi. Total Phenolic Content (TPC) varied from 245.32 ± 5.45 to 580.77 ± 13.10 (mg (GAE) per 100 g of dry weight) in methanolic extracts of S. bovinus and S. granulatus fruiting bodies, respectively. In ethyl acetate extracts, the highest TPC were obtained for S. variegatus (310 ± 9.68, mg (GAE)/100 g, dry matter), and the lowest means for S. luteus (105 ± 3.55, mg (GAE)/100 g dry weight). The ethyl acetate extracts of the tested Suillus species exhibited a stronger antioxidant activity (AA) to scavenge DPPH● and ABTS•+ than the methanolic ones, and the highest effects were determined for S. luteus (EC50, 0.15 ± 0.05 and 0.23 ± 0.05%, respectively). In the case of methanolic extracts, the highest AA were evaluated for S. granulatus. (EC50 for DPPH● and ABTS•+, 0.81 ± 0.30 and 0.95 ± 0.22%, respectively). The ABTS•+ scavenging potential varied from 0.25 ± 0.05 to 0.74 ± 0.10 (mmol/L, TROLOX equivalent, for S. granulatus and S. variegatus fruiting body extracts, respectively) in the ethyl acetate extracts. S. granulatus extracts demonstrated the widest range of antimicrobial effects against both gram-positive and gram-negative bacteria (from 11.7 ± 1.3 to 28.5 ± 3.3 mm against Pseudomonas aeruginosa and Bacillus mycoides, respectively); and against two fungal strains (up to 13.6 ± 0.4 mm on Meyerozyma guilliermondii) in agar disc diffusion tests. Our study revealed that methanolic extracts of the most tested Suillus sp. were not active enough against the tested parasites: Trypanosoma cruzi, Trypanosoma brucei, Leishmania infantum and Plasmodium falciparum. Only S. variegatus extracts showed good antiprotozoal effects against P. falciparum (12.70 µg/mL). Cytotoxic activity was observed on human diploid lung cells MRC-5 SV2 by S. granulatus extracts (64.45 µg/mL). For comparative purposes, extracts of other common Lithuanian fungi, such as Xerocomus sp. (X. badius, X. chrysenteron and X. subtomentosus), Tylopilus felleus, Phallus impudicus and Pycnoporus cinnabarinus were investigated for their activity. The P. cinnabarinus extracts demonstrated the highest and broadest overall effects: 1.32 µg/mL against T. brucei, 1.46 µg/mL against P. falciparum, 3.93 µg/mL against T. cruzi and 21.53 µg/mL against L. infantum. Additionally, this extract exhibited strong cytotoxicity on MRC-5 cells (13.05 µg/mL). The investigation of bioactive fungal metabolites is important for the development of a new generation of antioxidants, antimicrobials, antiparasitic and anticancer agents.

Microalgae in health care and functional foods: β-glucan applications, innovations in drug delivery and synthetic biology

Microalgae are emerging as a key player in healthcare, functional foods, and sustainable biotech due to their capacity to produce bioactive compounds like β-glucans, omega-3 fatty acids, and antioxidants in an eco-friendly manner. This review comprehensively discusses the role of microalgae in healthcare and functional foods, focusing particularly on β-glucan therapeutics, drug delivery innovations, and synthetic biology applications. In healthcare, microalgae-derived compounds show immense promise for treating diseases, boosting immunity, and tackling oxidative stress. Euglena-derived paramylon, a type of β-glucan, has shown potential in various medical applications, including immunomodulation and anticancer therapy. Synthetic biology and bioprocess engineering are enhancing microalgae's therapeutic and nutritional value, with applications in drug delivery and personalized medicine. To maximize the potential of microalgae, further research and development are needed to address scalability, regulatory alignment, and consumer acceptance, with a focus on interdisciplinary collaboration and sustainable practices to align healthcare innovation with environmental conservation.

Beneficial effects of pleuran on asthma control and respiratory tract-infection frequency in children with perennial asthma

The aim of this study was to evaluate the effects of pleuran (β-glucan isolated from Pleurotus ostreatus) on asthma control and respiratory morbidity in children on conventional GINA-based asthma treatment who had partially controlled perennial asthma. A double-blind, placebo-controlled multicentre clinical trial with a 2-arm, parallel design was conducted across three countries; 230 children aged 7 to 17 years were randomised (1:1) into an active group (receiving a pleuran/vitamin C combination) or a placebo group (receiving vitamin C only). This study consisted of 24 weeks of treatment (2 capsules a day) and then 24 weeks of follow-up. The primary endpoints included the effects of active treatment versus placebo on asthma control and respiratory tract infections (RTIs). Secondary endpoints included changes in the following measures: number of asthma exacerbations, with or without respiratory infection; quality of life of both asthmatic children and their caregivers; spirometric indices; fractional exhaled nitric oxide (FeNO) levels; safety after 24 weeks of treatment and also after the full 48-week study period. Overall, 206 children completed this study; 113 of these children were in the active group and received a pleuran/vitamin C combination for 24 weeks. After the 24-week treatment period, children below 12 years of age who were in the active group achieved significant improvements in asthma control compared to those in the placebo group (21.8 ± 3.5 vs. 20.3 ± 4.0; P = 0.02); while children at least 12 years old who were in the active group reported lower numbers of RTIs (0.7 ± 1.0 vs. 1.9 ± 1.7; P = 0.002) compared to children of this age in the placebo group. In addition, children below 12 years of age in the active group showed a significant decrease in asthma exacerbations compared to those in the placebo group (2.5 ± 1.6 vs. 3.3 ± 1.9; P = 0.05). At the end of the 48-week trial, a statistically significant improvement in asthma control was observed in 84.7% of children who received pleuran/vitamin C treatment compared to 67.0% of children who received vitamin C only (P = 0.01). The pleuran/vitamin C combined treatment was safe and well-tolerated, and no related serious adverse events were reported. This study highlights the favourable safety profile of pleuran/vitamin C supplementation and demonstrates positive effects of this treatment on asthma control and RTI incidence in children with allergic perennial asthma that was partially controlled by conventional therapy.

The immune response of upper and lower airway epithelial cells to Aspergillus fumigatus and Candida albicans-derived β-glucan in Th17 type cytokine environment

The fungal cell wall component β-glucan activates inflammation via the Dectin-1 receptor and IL-17 coordinates the antifungal immunity. However, the molecular crosstalk between IL-17, Dectin-1, and β-glucan in epithelial cells and fungal immunity remains unclear. We investigated the impact of A.fumigatus-derived β-glucan (AFBG) and C.albicans-derived β-glucan (CABG) on Dectin-1 and cytokines in nasal epithelial cells (NECs) and bronchial epithelial cells (BECs) in the presence of IL-17. CABG reduced BEC viability more than AFBG despite similar Dectin-1 expression. IL-17 reduced β-glucan-dependent Dectin-1 expression in NECs but increased it in BECs after 12 h. AFBG synergized with IL-17, enhancing pro-inflammatory cytokines and chemokine expressions. IL-6 and IL-8 production increased in the presence of IL-17. Th17 cytokine influenced the Dectin-1 response to fungal β-glucan in NECs and BECs, impacting the initiation and nature of epithelial cell reactions to AFBG and CABG. Uncovering the molecular mechanisms of fungal β-glucans in the respiratory tract could lead to novel strategies for preventing fungal diseases.

Effect of a Pleuran-Based Supplement on Salivary IgA Secretion in Children With Recurrent Respiratory Infections

Background

ß-glucans isolated from natural sources have demonstrated pluripotent immunomodulatory potential, making them a promising supportive treatment for the management of recurrent respiratory infections (RRIs) in children. This study aimed to evaluate the effects of a pleuran-based supplement (ß-glucan isolated from Pleurotus ostreatus in combination with vitamin D and zinc) on mucosal immunity -through modulating salivary secretory immunoglobulin A (sIgA) levels -in children with RRIs.

Methods

This monocentric, prospective, open-label pilot study investigated the effect of an orally administered pleuran/vitamin D/zinc supplement (1-2 chewable tablets daily depending on body weight) on the dynamics of sIgA secretion measured in saliva samples collected at three timepoints: at baseline and after 4-6 and 8-10 days.

Results

This study included 49 children aged 6-11 years (mean age: 8.2 ± 1.6 years) with a history of one or more of the following conditions in the inclusion criteria: RRIs, allergy, and asthma. After 8-10 days with daily administration of the chewable pleuran/vitamin D/zinc supplement, children exhibited a statistically significant increase in salivary sIgA concentrations compared with baseline (227 ± 211 µg/mL; P = 0.045). No adverse events were observed during the course of the study in relation to the administration of pleuran-based supplement.

Conclusions

We demonstrated the beneficial effects of the short-term administration of a pleuran-based chewable supplement on mucosal immunity through increasing salivatory sIgA levels. This study confirms the favourable safety profile of this pleuran/vitamin D/zinc combination, which could be beneficial for children with acute or recurrent respiratory infections, including children with allergies and/or asthma. Moreover, the significant increases in salivary sIgA concentrations that were observed after a few days of supplementation support the use of pleuran in not only the prevention but also the treatment of acute respiratory infections.

Chitosan and its derivatives: A novel approach to gut microbiota modulation and immune system enhancement

Chitosan, a biopolymer derived from the deacetylation of chitin found in crustacean shells and certain fungi, has attracted considerable attention for its promising health benefits, particularly in gut microbiota maintenance and immune system modulation. This review critically examines chitosan's multifaceted role in supporting gut health and enhancing immunity, beginning with a comprehensive overview of its sources, chemical structure, and its dual function as a dietary supplement and biomaterial. Chitosan's prebiotic effects are highlighted, with a focus on its ability to selectively stimulate beneficial gut bacteria, such as Bifidobacteria and Lactobacillus, while enhancing gut barrier integrity and inhibiting the growth of pathogenic microorganisms. The review delves deeply into chitosan's immunomodulatory mechanisms, including its impact on antigen-presenting cells, cytokine profiles, and systemic immune responses. A detailed comparative analysis assesses chitosan's efficacy relative to other prebiotics and immunomodulatory agents, examining challenges related to bioavailability and metabolic activity. Beyond its role in gut health, this review explores chitosan's potential as a dual-action agent that not only supports gut microbiota but also fortifies immune resilience. It introduces emerging research on novel chitosan derivatives, such as chitooligosaccharides, and evaluates their enhanced bioactivity for functional food applications. Special attention is given to sustainability, with an exploration of alternative, plant-based sources of chitosan and their implications for both health and environmental stewardship. Also, the review identifies new research avenues, such as the growing interest in chitosan's role in the gut-brain axis and its potential mental health benefits through microbial interactions. By addressing these innovative areas, the review aims to shift the focus from basic health effects to chitosan's broader impact on public health. The findings encourage further exploration, particularly through human trials, and emphasize chitosan's untapped potential in revolutionizing health and disease management.

Efficacy of yeast beta-glucan 1,3/1,6 supplementation on respiratory infection, fatigue, immune markers and gut health among moderate stress adults in Klang Valley of Malaysia: protocol for a randomised, double-blinded, placebo-controlled, parallel-group study

INTRODUCTION

Yeast beta-glucan (YBG) are recognised for enhancing the immune system by activating macrophages, a key defence mechanism. Given the global prevalence and impact of upper respiratory tract infections (URTIs) on productivity and healthcare costs, YBG has shown promise as a potential therapeutic and preventive strategy for recurrent respiratory tract infections. However, little is known regarding the efficacy of YBG at lower dosages in relation to URTI, fatigue, immune response and uncertainties of how they affect the gut microbiota composition.

METHODS AND ANALYSIS

This 12-week randomised, double-blinded, placebo control, parallel-group clinical trial aims to evaluate the efficacy of YBG 1,3/1,6 on respiratory tract infection, fatigue, immune markers and gut health among adults with moderate stress. The study involves 198 adults aged 18-59 years with moderate stress levels as assessed using Perceived Stress Scale 10 (score 14-26) and Patient Health Questionnaire 9 (score ≥9); and had symptoms of common colds for the past 6 months as assessed using Jackson Cold Scale. These participants will be randomised into three groups, receiving YBG 1,3/1,6 at either 120 mg, 204 mg or a placebo. The outcomes measures include respiratory infection symptoms, fatigue, mood state and quality of life assessed using Wisconsin Upper Respiratory Symptoms Scale, Multidimensional Fatigue Inventory, Profile of Mood State and Short Form 36 Health Survey Questionnaire, respectively. In addition, full blood analysis and assessment of immune, inflammatory and oxidative stress biomarkers will be taken. Secondary outcome includes gut microbiota analysis using stool samples via 16S rRNA sequencing.

ETHICS AND DISSEMINATION

The research protocol of the study was reviewed and approved by the Research Ethics Committee of Universiti Kebangsaan Malaysia (UKM/PPI/111/8/JEP-2023-211). The findings will be disseminated to participants, healthcare professionals and researchers via conference presentations and peer-reviewed publications.

TRIAL REGISTRATION NUMBER

ISRCTN48336189.

Reviewing the audacity of elixirs of inflammatory bowel disease from mushroom β-glucans: The solved and unresolved

BACKGROUND

Mushrooms are known as the elixirs of life, they are packed with various bioactive compounds that make them not only tasty but also healthy. Thus, they not just fall within the category of nutritional foods, but also functional foods. When medicinal bioactive components are sought after from every other available resource, these natural reservoirs are easily accessible therapeutic sources. Of the various bioactive that mushrooms have to offer, β-glucans are the most enriching.

METHODS

β-glucans are available in other sources as well, but their relative abundance is higher in mushrooms. Amidst the cascade of biological benefits from β-glucans, anti-inflammatory benefits are highly promising. In this present review, the anti-inflammatory properties of mushroom β-glucans have been discussed and its specific contributions against inflammatory bowel disease have been reviewed.

DISCUSSION

What is known regarding the modulus operandi of β-glucans against inflammatory bowel disease has been summarized and the gaps and lapses in the current understanding highlighted. This is the first state-of-the-art review that presents a comprehensive executive summary and discussion in this subject area.

Untapping the potential of algae for β-glucan production: A review of biological properties, strategies for enhanced production and future perspectives

β-Glucan, a naturally occurring polymer of glucose, is found in bacteria, algae, fungi, and higher plants (barley, oats, cereal seeds). Recently, β-glucan has gained attention due to its multiple biological roles, like anticancer, anti-inflammatory, and immunomodulatory effects. Globally, bacteria, mushrooms, yeast and cereals are used as conventional sources of β-glucan. However, obtaining it from these sources is challenging due to low quantity, complex branched structure, and costly extraction process. Algae have emerged as a potential sustainable alternative source of β-glucan to conventional sources due to several advantages including unique structural and functional advantages, higher yields, faster growth rates, and large-scale production in a controlled environment. Additionally, extracting β-glucan from microalgal sources is relatively easy and can be done without altering the structure of β-glucan. Some algal species, such as Euglena spp., are reported to contain higher β-glucan content than conventional β-glucan sources. This review highlights the current research and opportunities associated with algae-derived β-glucan and their biological roles. The challenges, research gaps and strategies to enhance algae-based β-glucan production and the need for further research in this promising area are also discussed. Future research can be extended to comprehend the cellular and molecular mechanisms via which β-glucan functions.

Effects of a β-glucan-enriched diet on biomarkers of oxidative stress, energy metabolism and lysosomal function in muscle tissue of European grayling (Thymallus thymallus L.)

Introduction

The grayling (Thymallus thymallus L.) has several advantages over other fish species that make it attractive for aquaculture and invest it with importance for food security. The study assessed the effects of a β-glucan-enriched diet on biomarkers of oxidative stress, energy metabolism and lysosomal function in muscle tissue of European grayling (Thymallus thymallus L.).

Material and Methods

Sixty-six grayling weighing approximately 34 g were divided into equal control and experimental groups. A basal diet was fed to the control group and a β-glucan-enriched one was fed to the experimental group for 45 d. Lipid peroxidation (LP) level; oxidative protein modification (OPM); total antioxidant status (TAS); and superoxide dismutase (SOD), catalase (CAT), glutathione reductase, glutathione peroxidase (GPx), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate (LDH), succinate dehydrogenase (SDH), alanyl aminopeptidase, leucyl aminopeptidase, acid phosphatase (AcP) and β-N-acetylglucosaminidase (NAG) activities were assessed in the muscle tissue of fish euthanised after 15, 30 and 45 d of feeding.

Results

The β-glucan supplementation reduced LP, attenuated OPM and improved the TAS in muscle tissue. Increased SOD and CAT activity and maintenance of GPx activity in muscle tissue were the main mediators of these effects. They also affected energy metabolism through modulation of key enzymes and metabolites, including ALT, AST, LDH, SDH, AcP and NAG activity, and altered lactate and pyruvate levels. Multivariate analysis of variance, supported by high F-values and low P-values indicating statistical significance, highlighted the significant effect of β-glucans and feeding duration on markers of oxidative stress, antioxidant defences and TAS.

Conclusion

B-glucans altered the balance between aerobic and anaerobic metabolism, reduced OPM and modulated the transaminase response, affecting amino acid metabolism and the production of Krebs cycle intermediates.

"β-glucan signalling stimulates NOX-2 dependent autophagy and LC-3 associated autophagy (LAP) pathway"

β-Glucan, a complex polysaccharide derived from fungal and yeast cell walls, plays a crucial role in modulating immune responses through their interaction with receptors such as Dectin-1 and Complement receptor 3 (CR-3). This review provides an in-depth analysis of the molecular mechanisms by which β-glucans activate receptor-mediated signalling pathways, focusing particularly on the LC3-associated phagocytosis (LAP) and autophagy pathways. Hence, we explore how β-glucan receptor engagement stimulates NADPH oxidase 2 (NOX-2), leading to the intracellular production of significant level of reactive oxygen species (ROS) essential for both conventional autophagy and LAP. While significant progress has been made in elucidation of downstream signaling by glucans, the regulation of phago-lysosomal maturation and antigen presentation during LAP induction still remains less explored. This review aims to provide a comprehensive overview of these pathways and their regulation by β-glucans. By consolidating the current knowledge, we seek to highlight how these mechanisms can be leveraged for therapeutic applications, particularly in the context of tuberculosis (TB) management, where β-glucans could serve as host-directed adjuvant therapies to combat drug-resistant strains. Despite major advancements in this field, currently key research gaps still persist, including detailed molecular interactions between β-glucan receptors and NOX-2 and the translation of these findings to in-vivo models and clinical investigations. This review underscores the need for further research to explore the therapeutic potential of β-glucans in managing not only tuberculosis but also other diseases such as cancer, cardiovascular conditions, and metabolic disorders.

Chemical Characterization and In Vitro Evaluation of Glucans from Fermentation-Produced Nutraceutical Bionutri-AR1®: Antioxidant and Immunomodulatory Properties

Background: The consumption of nutraceuticals or food supplements has increased crucially, aiming to address nutrient deficits and enhance immune system function. To develop safe food products with unique nutritional and functional benefits, new production methods of these nutraceuticals such as the fermentative process have been gaining prominence for industrial applications. Bionutri-AR1® is a nutraceutical produced via this bioprocess, featuring a complex composition, that has been used to improve the immune systems of debilitated people. Objectives: Considering the various biological properties attributed to glucans, one of its main components, this study aims to structurally characterize and evaluate, in vitro, the antioxidant and immunomodulatory potential of the polymers from this nutraceutical to assess whether these polymers contribute to the product's reported biological effects. Methods/Results: Unlike previous reports, this study characterized by NMR, GC-MS, and Congo Red assay techniques two main glucans: a water-insoluble linear α-D-glucan with glycosidic bonds (1→4) and a soluble branched (1→3)- and (1→6)-linked β-glucan with a triple helix. Both glucans showed significant antioxidant activity, measured by their capacity to scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals. They were also capable of inducing the secretion of cytokines such as tumoral necrosis factor-alpha (TNF-α), interleukin 10 (IL-10), and interleukin 6 (IL-6), determined through capture enzyme-linked immunosorbent assay (ELISA), especially when co-stimulated with lipopolysaccharide (LPS). Conclusions: This suggests a dual action of these glucans in both proinflammatory and regulatory pathways. Future studies will describe the mechanisms by which these glucans, especially the insoluble ones, enhance immune system function, highlighting their potential use in immunotherapy.

Effects of Dietary Yeast β-1,3/1,6-D-Glucan on Immunomodulation in RAW 264.7 Cells and Methotrexate-Treated Rat Models

A new subclass of nutraceuticals, called immunoceuticals, is dedicated to immunological regulation. Although yeast-derived β-1,3/1,6-D-glucan shows promise as an immunoceutical candidate, further studies are needed to define its precise immune-enhancing processes and to standardize its use. Following methotrexate (MTX)-induced immunosuppression in rats, we evaluated the immunomodulatory efficacy of a highly pure and standardized β-1,3/1,6-D-glucan sample (YBG) in RAW 264.7 macrophages. In in vitro and in vivo models, YBG demonstrated remarkable immunomodulatory effects, such as repair of immune organ damage, elevation of blood cytokine levels, and enhanced phagocytosis and nitric oxide production in RAW 264.7 cells. These results are consistent with the established immunostimulatory properties of β-glucan. It is noteworthy that this research indicates the potential of YBG as an immunomodulatory nutraceutical, as it is among the first to demonstrate immunological augmentation in an immunosuppression setting produced by MTX. Based on these observations, further investigation of YBG is warranted, particularly given its potential to emerge as a combination immunoceutical to mitigate immunosuppression and reduce the risk of infection in rheumatoid arthritis (RA) patients receiving long-term MTX therapy.

Advances in Microbial Exopolysaccharides: Present and Future Applications

Microbial exopolysaccharides (EPSs) are receiving growing interest today, owing to their diversity in chemical structure and source, multiple functions, and immense potential applications in many food and non-food industries. Their health-promoting benefits for humans deserve particular attention because of their various biological activities and physiological functions. The aim of this paper is to provide a comprehensive review of microbial EPSs, covering (1) their chemical and biochemical diversity, including composition, biosynthesis, and bacterial sources belonging mainly to lactic acid bacteria (LAB) or probiotics; (2) their technological and analytical aspects, especially their production mode and characterization; (3) their biological and physiological aspects based on their activities and functions; and (4) their current and future uses in medical and pharmaceutical fields, particularly for their prebiotic, anticancer, and immunobiotic properties, as well as their applications in other industrial and agricultural sectors.

A review of the fungal polysaccharides as natural biopolymers: Current applications and future perspective

As a unique natural resource, fungi are a sustainable source of lipids, polysaccharides, vitamins, proteins, and other nutrients. As a result, they have beneficial medicinal and nutritional properties. Polysaccharides are among the most significant bioactive components found in fungi. Increasing research has revealed that fungal polysaccharides (FPS) contain a variety of bioactivities, including antitumor, antioxidant, immunomodulatory, anti-inflammatory, hepatoprotective, cardioprotective, and anti-aging properties. However, the exact knowledge about FPS and their applications related to their future possibilities must be thoroughly examined to enhance a better understanding of this sustainable biopolymer source. Therefore, FPS' biological applications and their role in the food and feed industry, agriculture, and cosmetics applications were all discussed in this work. In addition, this review highlighted the mode of action of FPS on human diseases by regulating gut microbiota and discussed the mechanism of FPS as antioxidants in the living cell. The structure-activity connections of FPS were also highlighted and explored. Moreover, future perspectives were listed to pave the way for future studies of FPS applications. Hence, this study can be a scientific foundation for future FPS research and industrial applications.

Boosting Synergistic Antioxidant and Anti-Inflammatory Properties Blending Cereal-Based Nutraceuticals Produced Using Sprouting and Hydrolysis Tools

Nutraceuticals obtained from sprouted wheat and oat grains and processing by-products (bran and hull, respectively) naturally containing antioxidant and anti-inflammatory compounds were evaluated. The objective of this study was the development of a cereal-based nutraceutical formula combining extracts from sprouts and by-products and the exploration for potential synergetic effects in their bioactive properties. The antioxidant and anti-inflammatory capacities, glycemic index, phytic acid, and β-glucan of individual wheat bran hydrolysate (EH-WB), sprouted wheat (SW), oat hull hydrolysate (EH-OH), sprouted oat (SO), and combined ingredients (CI 1, CI 2, and CI3) were used to tailor an optimal nutraceutical formula. The three blend ingredients (CI 1, CI2, and CI3) were formulated at different ratios (EH-WB:SW:EH-OH:SO; 1:1:1:1, 2:1:2:1, and 1:2:1:2, w:w:w:w, respectively). The resulting mixtures showed total phenol (TPs) content ranging from 412.93 to 2556.66 µmol GAE 100 g-1 and antioxidant capacity values from 808.14 to 22,152.54 µmol TE 100 g-1 (ORAC) and 1914.05 to 7261.32 µmol TE 100 g-1 (ABTS•+), with Fe3+ reducing ability from 734. 02 to 8674.51 mmol reduced Fe 100 g-1 (FRAP) for the individual ingredients produced from EH-WB and EH-OH, where high antioxidant activity was observed. However, the anti-inflammatory results exhibited an interesting behavior, with a potentially synergistic effect of the individual ingredients. This effect was observed in CI2 and CI3, resulting in a higher ability to inhibit IL-6 and TNF-α than expected based on the anti-inflammatory values of their individual ingredients. Similar to the antioxidant properties, oat-based ingredients significantly contributed more to the anti-inflammatory properties of the overall mixture. This contribution is likely associated with the β-glucans and avenanthramides present in oats. To ensure the bioaccessibility of these ingredients, further studies including simulated digestion protocols would be necessary. The ingredient formulated with a 2:1 hydrolysate-to-sprout ratio was the most effective combination, reaching higher biological characteristics.

Effects of a β-Glucan-Rich Blend of Medicinal Mushrooms and Botanicals on Innate Immune Cell Activation and Function Are Enhanced by a Very Low Dose of Bovine Colostrum Peptides

Nutraceutical immune support offers potential for designing blends with complementary mechanisms of action for robust support of innate immune alertness. We documented enhanced immune activation when bovine colostrum peptides (BC-Pep) were added to an immune blend (IB) containing β-glucans from yeast, shiitake, maitake, and botanical non-β-glucan polysaccharides. Human peripheral blood mononuclear cells (PBMCs) were cultured with IB, BC-Pep, and IB + BC-Pep for 20 h, whereafter expression of the activation marker CD69 was evaluated on NK cells, NKT cells, and T cells. Cytokine levels were tested in culture supernatants. PBMCs were co-cultured with K562 target cells to evaluate T cell-mediated cytotoxicity. IB + BC-Pep triggered highly significant increases in IL-1β, IL-6, and TNF-α, above that of cultures treated with matching doses of either IB or BC-Pep. NK cell and T cell activation was increased by IB + BC-Pep, reaching levels of CD69 expression several fold higher than either BC-Pep or IB alone. IB + BC-Pep significantly increased T cell-mediated cytotoxic killing of K562 target cells. This synergistic effect suggests unique amplification of signal transduction of NK cells and T cells due to modulation of IB-induced signaling pathways by BC-Pep and is of interest for further pre-clinical and clinical testing of immune defense activity against virally infected and transformed cells.

Clinical Studies Using Topical Melatonin

Melatonin is ubiquitously present in all animals and plants, where it exerts a variety of physiological activities thanks to its antioxidant properties and its key role as the first messenger of extracellular signaling functions. Most of the clinical studies on melatonin refer to its widespread oral use as a dietary supplement to improve sleep. A far smaller number of articles describe the clinical applications of topical melatonin to treat or prevent skin disorders by exploiting its antioxidant and anti-inflammatory activities. This review focuses on the clinical studies in which melatonin was applied on the skin as a photoprotective, anti-aging, or hair growth-promoting agent. The methodologies and results of such studies are discussed to provide an overall picture of the state of the art in this intriguing field of research. The clinical studies in which melatonin was applied on the skin before exposure to radiation (UV, sunlight, and high-energy beams) were all characterized by an appropriate design (randomized, double-blind, and placebo-controlled) and strongly support its clinical efficacy in preventing or reducing skin damage such as dermatitis, erythema, and sunburn. Most of the studies examined in this review do not provide a clear demonstration of the efficacy of topical melatonin as a skin anti-aging or as a hair growth-promoting agent owing to limitations in their design and/or to the use of melatonin combined with extra active ingredients, except for one trial that suggests a possible beneficial role of melatonin in treating some forms of alopecia in women. Further research efforts are required to reach definitive conclusions concerning the actual benefits of topical melatonin to counteract skin aging and hair loss.

Genetically engineering of Saccharomyces cerevisiae for enhanced oral delivery vaccine vehicle

As a series of our previous studies reported, recombinant yeast can be the oral vaccines to deliver designed protein and DNA, as well as functional shRNA, into dendritic cells (DCs) in mice for specific immune regulation. Here, we report the further optimization of oral yeast-based vaccine from two aspects (yeast characteristics and recombinant DNA constitution) to improve the effect of immune regulation. After screening four genes in negative regulation of glucan synthesis in yeast (MNN9, GUP1, PBS2 and EXG1), this research combined HDR-based genome editing technology with Cre-loxP technology to acquire 15 gene-knockout strains without drug resistance-gene to exclude biosafety risks; afterward, oral feeding experiments were performed on the mice using 15 oral recombinant yeast-based vaccines constructed by the gene-knockout strains harboring pCMV-MSTN plasmid to screen the target strain with more effective inducing mstn-specific antibody which in turn increasing weight gain effect. And subsequently based on the selected gene-knockout strain, the recombinant DNA in the oral recombinant yeast-based vaccine is optimized via a combination of protein fusion expression (OVA-MSTN) and interfering RNA technology (shRNA-IL21), comparison in terms of both weight gain effect and antibody titer revealed that the selected gene-knockout strain (GUP1ΔEXG1Δ) combined with specific recombinant DNA (pCMV-OVA-MSTN-shIL2) had a better effect of the vaccine. This study provides a useful reference to the subsequent construction of a more efficient oral recombinant yeast-based vaccine in the food and pharmaceutical industry.

β-Glucans obtained from fungus for wound healing: A review

The cell surface of fungus contains a large number of β-glucans, which exhibit various biological activities such as immunomodulatory, anti-inflammatory, and antioxidation. Fungal β-glucans with highly branched structure show great potential as wound healing reagents, because they can stimulate the expression of many immune- and inflammatory-related factors beneficial to wound healing. Recently, the wound healing ability of many fungal β-glucans have been investigated in animals and clinical trials. Studies have proved that fungal β-glucans can promote fibroblasts proliferation, collagen deposition, angiogenesis, and macrophage infiltration during the wound healing process. However, the development of fungal β-glucans as wound healing reagents is not systematically reviewed till now. This review discusses the wound healing studies of β-glucans obtained from different fungal species. The structure characteristics, extraction methods, and biological functions of fungal β-glucans with wound healing ability are summarized. Researches about fungal β-glucan-containing biomaterials and structurally modified β-glucans for wound healing are also involved.

β-glucan-induced disease resistance in plants: A review

Systemic acquired resistance (SAR) and induced systemic resistance (ISR) are caused by various factors, including both pathogenic and non-pathogenic ones. β-glucan primarily originates from bacteria and fungi, some species of these organisms work as biological agents in causing diseases. When β-glucan enters plants, it triggers the defense system, leading to various reactions such as the production of proteins related to pathogenicity and defense enzymes. By extracting β-glucan from disturbed microorganisms and using it as an inducing agent, plant diseases can be effectively controlled by activating the plant's defense system. β-glucan plays a crucial role during the interaction between plants and pathogens. Therefore, modeling the plant-pathogen relationship and using the molecules involved in this interaction can help in controlling plant diseases, as pathogens have genes related to resistance against pathogenicity. Thus, it is reasonable to identify and use biological induction agents at a large scale by extracting these compounds.

Recent Progress in 1,2-cis glycosylation for Glucan Synthesis

Controlling the stereoselectivity of 1,2-cis glycosylation is one of the most challenging tasks in the chemical synthesis of glycans. There are various 1,2-cis glycosides in nature, such as α-glucoside and β-mannoside in glycoproteins, glycolipids, proteoglycans, microbial polysaccharides, and bioactive natural products. In the structure of polysaccharides such as α-glucan, 1,2-cis α-glucosides were found to be the major linkage between the glucopyranosides. Various regioisomeric linkages, 1→3, 1→4, and 1→6 for the backbone structure, and 1→2/3/4/6 for branching in the polysaccharide as well as in the oligosaccharides were identified. To achieve highly stereoselective 1,2-cis glycosylation, including α-glucosylation, a number of strategies using inter- and intra-molecular methodologies have been explored. Recently, Zn salt-mediated cis glycosylation has been developed and applied to the synthesis of various 1,2-cis linkages, such as α-glucoside and β-mannoside, via the 1,2-cis glycosylation pathway and β-galactoside 1,4/6-cis induction. Furthermore, the synthesis of various structures of α-glucans has been achieved using the recent progressive stereoselective 1,2-cis glycosylation reactions. In this review, recent advances in stereoselective 1,2-cis glycosylation, particularly focused on α-glucosylation, and their applications in the construction of linear and branched α-glucans are summarized.